Form 4 for LENZ LENZ Therapeutics, Inc.
Accepted 2026-03-30 00:00:00 ET · period of report 2026-03-27 · accession 0001713795-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-27 | LENZ | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | P - Purchase | $8.95 | +28.1K | 77.3K | +57% | +$251.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-27 | P | A | 28,089 | $8.95 | 77,289 | D | — | — | (F1) Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |